A recent phase III study of inavolisib (INAVO120, NCT04191499) showed that inavolisib in combination with palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, and fulvestrant more than doubled progression-free survival compared with palbociclib and fulvestrant alone (15.0 months vs 7.3 months) in endocrine therapy-resistant PIK3CA-mutated HR+ HER2− advanced breast cancer patients.71 The gene discussed is PIK3CA; the disease is breast cancer.